Top

BMC Musculoskeletal Disorders

Published in:

Open Access 01-12-2014 | Research article

Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study

Authors: Wei Shen, Russel Burge, April N Naegeli, Jeremy Shih, Jahangir Alam, Deborah T Gold, Stuart Silverman

Published in: BMC Musculoskeletal Disorders | Issue 1/2014

Abstract

Background

We explored psychometric properties of the Osteoporosis Assessment Questionnaire 2.0 in terms of reliability, validity, and responsiveness with generic, clinical, demographic, and preference-based data collected from a population of postmenopausal women with osteoporosis.

Methods

The Multiple Outcomes of Raloxifene Evaluation study was a randomized, placebo-controlled, multinational clinical trial evaluating efficacy and safety of raloxifene. The Osteoporosis Assessment Questionnaire 2.0, a generic quality of life measure (Nottingham Health Profile), and a preference-based measure (Health Utilities Index) were administered at baseline and annually. Psychometric properties of the 14 Osteoporosis Assessment Questionnaire 2.0 domains were evaluated by standard statistical techniques.

Results

This study included a subset of 1477 women from the Multiple Outcomes of Raloxifene Evaluation study population completing the questionnaires. Mean (standard deviation) age was 68.4 (6.8) years. Prevalent vertebral fractures were found in 70% (n =1038) of women. Internal consistency was >0.7 in 9 Osteoporosis Assessment Questionnaire 2.0 domains. Correlations were moderate and significant for similar Osteoporosis Assessment Questionnaire 2.0 domain scores, Nottingham Health Profile domains, and Health Utilities Index scores. All but 2 Osteoporosis Assessment Questionnaire 2.0 domains distinguished between patients with or without prevalent vertebral fractures and detected worsening with increased number of vertebral fractures. Women with ≥1 incident vertebral fracture generally had a greater worsening in Osteoporosis Assessment Questionnaire 2.0 scores (excluding social activity and support of family and friends) from baseline to study endpoint compared with women without incident vertebral fractures.

Conclusions

Most domains in the Osteoporosis Assessment Questionnaire 2.0 demonstrated robust psychometric properties; however, several domains not showing these criteria may need to be reassessed and removed for a potentially shorter and validated version of the Osteoporosis Assessment Questionnaire.

Available only for authorised users

North American Menopause Society: Management of osteoporosis in postmenopausal women: 2010 position statement. Menopause. 2010, 17: 25-54. 10.1097/gme.0b013e3181c617e6.CrossRef

NIH Consensus Development Panel on Osteoporosis Prevention: Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001, 285: 785-795. 10.1001/jama.285.6.785.CrossRef

NIH Osteoporosis and Related Bone Diseases National Resource Cente: Osteoporosis Handout on Health. NIH Publication No. 11–5158. Edited by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Information Clearinghouse. 2014, Bethesda, MD: National Institutes of Health,http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/osteoporosis_hoh.asp,

National Osteoporosis Foundation: America’s Bone Health: The State of Osteoporosis and Low Bone Mass in our Nation. 2002, Washington D.C: The Foundation

World Health Organization: Constitution of the World Health Organization. 1947, Geneva: World Health Organization

Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation study: The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation study. Arthritis Rheum. 2001, 44: 2611-2619. 10.1002/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N.CrossRefPubMed

Gold TT, Shipp KM, Pieper CF, Duncan PW, Martinez S, Lyles KW: Group treatment improves trunk strength and psychological status in older women with vertebral fractures: Results of a randomized clinical trial. J Am Geriatr Soc. 2004, 52: 1471-1478. 10.1111/j.1532-5415.2004.52409.x.CrossRefPubMed

Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR: The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998, 128: 793-800. 10.7326/0003-4819-128-10-199805150-00001.CrossRefPubMed

Randell AG, Bhalerao N, Nguyen TV, Sambrook PN, Eisman JA, Silverman SL: Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire. J Rheumatol. 1998, 25: 1171-1179.PubMed

10.

Silverman SL: The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis. Qual Life Res. 2000, 9 (Suppl 1): 767-774.CrossRef

11.

Silverman SL, Mason J, Greenwald M: The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid self assessment measure of quality of life in osteoporosis [abstract]. J Bone Miner Res. 1993, 8 (Suppl 1): s343-

12.

Silverman SL, Go K, Tou C: What is the difference in quality of life between patients with osteopenia and patients with osteoporotic fracture?. Arthritis Rheum. 1996, 39 (Suppl 9): S88-

13.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999, 282: 637-645. 10.1001/jama.282.7.637.CrossRefPubMed

14.

Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J: Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000, 15: 1384-1392. 10.1359/jbmr.2000.15.7.1384.CrossRefPubMed

15.

Silverman SL, Shen W, Minshall ME, Xie S, Moses KH: Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Rheumatol. 2007, 34: 140-144.PubMed

16.

Committee for Medical Products for Human Use (CHMP): Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Edited by: Efficacy Working Party, Committee For Medicinal Products For Human Use (CHMP). 2005, London, UK,http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf,

17.

Food and Drug Administration: Guidance for industry: patient report outcome measures: use in clinical medical product development to support labeling claims. Guidance document. Edited by: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research. Food and Drug Administration. 2009, Silver Spring, MD,http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf,

18.

Hunt SM, McKenna SP, McEwen J, Williams J, Papp E: The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med. 1981, 15A (3 Pt 1): 221-229.

19.

Feeny DH, Furlong W, Boyle M, Torrance GW: Health utilities index. Quality of Life and Pharmacoeconomics in Clinical Trials. Edited by: Spilker B. 1996, Philadelphia: Lippincott-Raven, 85-95.

20.

Nunnally JC, Bernstein IH: Psychometric Theory. 1994, New York: McGraw-Hill, 3

21.

Guilford JP, Fruchter B: Fundamental Statistics in Psychology and Education. 1973, New York: McGraw-Hill

22.

Roux C, Wyman A, Hooven FH, Gehlbach SH, Adachi JD, Chapurlat RD, Compston JE, Cooper C, Díez-Pérez A, Greenspan SL, Lacroix AZ, Netelenbos JC, Pfeilschifter J, Rossini M, Saag KG, Sambrook PN, Silverman S, Siris ES, Watts NB, Boonen S, GLOW Investigators: Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int. 2012, 23: 2863-2871. 10.1007/s00198-012-1935-8.CrossRefPubMedPubMedCentral

23.

Borgström F, Lekander I, Ivergård M, Ström O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jürisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson AN, Jönsson B, Kanis JA: The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporos Int. 2013, 24: 811-823. 10.1007/s00198-012-2240-2.CrossRefPubMed

24.

Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, Boonen S, Black D, Adachi JD, HORIZON Pivotal Fracture Trial: Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone. 2011, 48: 1298-1304. 10.1016/j.bone.2011.03.719.CrossRefPubMed

25.

World Health Organization: Assessment of Osteoporosis at Primary Health Care Level. Report of a WHO Study Group. WHO Technical Report Series, No. 843. 2004, Geneva: World Health Organization

26.

Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, Sebaldt RJ, Petrie A, Tenenhouse A, Stephenson GF, Papaioannou A, Guyatt GH, Goldsmith CH: The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord. 2002, 3: 11-10.1186/1471-2474-3-11.CrossRefPubMedPubMedCentral

27.

Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL: The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol. 2003, 30: 1579-1583.PubMed

28.

Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA: Deterioration in the quality of life following hip fracture: a prospective study. Osteoporos Int. 2000, 11: 460-466. 10.1007/s001980070115.CrossRefPubMed

29.

Siris ES, Chen YT, Abbott A, Barrett-Connor E, Miller PD, Wehren LE, Berger ML: Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004, 164: 1108-1112. 10.1001/archinte.164.10.1108.CrossRefPubMed

30.

Gehlbach SH, Fournier M, Bigelow C: Recognition of osteoporosis by primary care physicians. Am J Public Health. 2002, 92: 271-273. 10.2105/AJPH.92.2.271.CrossRefPubMedPubMedCentral

31.

Kanis JA, Minne WH, Meunier PJ, Ziegler R, Allender E: Quality of life and vertebral osteoporosis. Osteoporos Int. 1992, 2: 161-163. 10.1007/BF01623919.CrossRefPubMed

32.

Leidig G, Minne HW, Sauer P, Wüster C, Wüster J, Lojen M, Raue F, Zigler R: A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner. 1990, 8: 217-229. 10.1016/0169-6009(90)90107-Q.CrossRefPubMed

33.

Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Liberman U, Minne H, Reeve J, Reginster JY, de Vernejoul MC, Wiklund I: Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int. 1997, 7: 36-38.CrossRefPubMed

34.

Ross PD, Davis JW, Epstein RS, Wasnich RD: Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol. 1994, 47: 231-239. 10.1016/0895-4356(94)90004-3.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/15/374/prepub

Title: Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study
Authors: Wei Shen
Russel Burge
April N Naegeli
Jeremy Shih
Jahangir Alam
Deborah T Gold
Stuart Silverman
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Musculoskeletal Disorders / Issue 1/2014
Electronic ISSN: 1471-2474
DOI: https://doi.org/10.1186/1471-2474-15-374

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Internet-mediated physiotherapy and pain coping skills training for people with persistent knee pain (IMPACT – knee pain): a randomised controlled trial protocol

MALDI-TOF-MS serum protein profiling for developing diagnostic models and identifying serum markers for discogenic low back pain

The fabella syndrome - a rare cause of posterolateral knee pain: a review of the literature and two case reports

Does Low-intensity pulsed ultrasound treatment repair articular cartilage injury? A rabbit model study

Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis

Web-based therapeutic exercise resource center as a treatment for knee osteoarthritis: a prospective cohort pilot study